A detailed history of Harbour Investments, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Harbour Investments, Inc. holds 8,090 shares of GILD stock, worth $739,021. This represents 0.02% of its overall portfolio holdings.

Number of Shares
8,090
Previous 9,055 10.66%
Holding current value
$739,021
Previous $621,000 9.18%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$66.59 - $83.99 $64,259 - $81,050
-965 Reduced 10.66%
8,090 $678,000
Q2 2024

Jul 26, 2024

BUY
$63.15 - $72.88 $128,636 - $148,456
2,037 Added 29.03%
9,055 $621,000
Q1 2024

Jul 22, 2024

BUY
$71.58 - $87.29 $25,625 - $31,249
358 Added 5.38%
7,018 $514,000
Q4 2023

Feb 16, 2024

BUY
$73.27 - $83.09 $32,898 - $37,307
449 Added 7.23%
6,660 $539,000
Q3 2023

Nov 15, 2023

SELL
$73.94 - $80.67 $29,502 - $32,187
-399 Reduced 6.04%
6,211 $465,000
Q2 2023

Aug 14, 2023

SELL
$76.01 - $86.7 $1,140 - $1,300
-15 Reduced 0.23%
6,610 $509,000
Q1 2023

May 15, 2023

BUY
$77.31 - $88.08 $24,120 - $27,480
312 Added 4.94%
6,625 $549,000
Q4 2022

Feb 15, 2023

BUY
$62.32 - $89.47 $105,445 - $151,383
1,692 Added 36.62%
6,313 $541,000
Q2 2022

Aug 15, 2022

SELL
$57.72 - $65.01 $2,424 - $2,730
-42 Reduced 0.9%
4,621 $286,000
Q4 2021

Feb 16, 2022

SELL
$64.88 - $73.64 $638,159 - $724,323
-9,836 Reduced 67.84%
4,663 $339,000
Q3 2021

Nov 15, 2021

SELL
$67.69 - $73.03 $165,705 - $178,777
-2,448 Reduced 14.45%
14,499 $1.01 Million
Q2 2021

Aug 16, 2021

BUY
$63.47 - $69.35 $173,336 - $189,394
2,731 Added 19.21%
16,947 $1.17 Million
Q1 2021

Aug 17, 2021

BUY
$60.0 - $68.46 $726,540 - $828,982
12,109 Added 574.7%
14,216 $919,000
Q1 2021

May 12, 2021

BUY
$60.0 - $68.46 $126,420 - $144,245
2,107 New
2,107 $136,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Harbour Investments, Inc. Portfolio

Follow Harbour Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbour Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbour Investments, Inc. with notifications on news.